Table 4. Pharmacological treatment of preterm PDA according to the PDA treatment strategies.
| PT group (n = 67) |
PST group (n = 209) |
ST roup (n = 525) |
Total (n = 801) |
||
|---|---|---|---|---|---|
| Ibuprofen | Total | 64 (95.5%) | 208 (99.5%) | 515 (98.1%) | 787 (98.2%) |
| Oral | 2 (3.0%) | 121 (57.9%) | 152 (29.0%) | 275 (34.3%) | |
| IV | 62 (92.5%) | 85 (40.7%) | 356 (67.8%) | 503 (62.8%) | |
| Oral+IV | 0 (0.0%) | 2 (0.9%) | 7 (1.3%) | 9 (1.1%) | |
| Indomethacin | 2 (3.0%) | 1 (0.5%) | 10 (1.9%) | 13 (1.7%) | |
| Others | 1 (1.5%) | 0 (0.0%) | 0 (0.0%) | 1 (0.1%) |
PT, prophylactic treatment; PST, pre-symptomatic treatment; ST, symptomatic treatment; IV, intravenous; others, other medications used for treatment of preterm patent ductus arteriosus such as acetaminophen.